Anais Badia, DO
Dermatology · Fort Myers, FLNPI 1609051887
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Pfizer accounts for 64.2% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $5,560 and has fallen 79.9% since, to $1,119 in 2025.
Across 144 payments — averaging $62.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- AbbVie$619
- Johnson & Johnson$461
- Arcutis Biotherapeutics, Inc.$257
- Regeneron Healthcare Solutions, Inc.$208
- UCB, Inc.$194
- plus $2K from 23 others
Across 269 payments — averaging $3098.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$240K
- Boehringer Ingelheim$211K
- Sanofi US Services Inc.$90K
- Incyte Corporation$51K
- Ichnos Glenmark Innovation Inc$51K
- Pfizer$42K
- plus $148K from 9 others
What the payments were for
- Speaking & faculty fees$5,25058%
- Food & beverage$3,49539%
- Education$3033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $5,809 |
| AbbVie(2 entities) | 30 | $619 |
| Johnson & Johnson | 15 | $461 |
| Arcutis Biotherapeutics, Inc. | 10 | $257 |
| Regeneron Healthcare Solutions, Inc. | 4 | $208 |
| UCB, Inc. | 3 | $194 |
| Galderma Laboratories, L.p. | 5 | $191 |
| Sanofi | 7 | $166 |
| Amgen | 3 | $159 |
| Lilly USA, LLC | 6 | $157 |
| Dermavant Sciences, Inc. | 8 | $149 |
| Incyte Corporation | 4 | $89 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Biofrontera Inc. | 3 | $60 |
| Merck | 3 | $58 |
| Sun Pharmaceutical Industries Inc. | 3 | $58 |
| Kerecis Limited | 1 | $57 |
| LEO Pharma Inc. | 2 | $50 |
| EPI Health, LLC | 2 | $42 |
| Novartis | 2 | $37 |
| Boehringer Ingelheim | 2 | $32 |
| LNHC, Inc | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $20 |
| Sebela Pharmaceuticals Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $14 |
| Organon | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $12 |
| Strata Skin Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,048 in reported general payments places this provider in the 75th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $120,419 |
| Humira(Cf) PenAdalimumab | 15 | $104,502 |
| Dupixent SyringeDupilumab | 13 | $59,516 |
| OtezlaApremilast | 12 | $58,788 |
| Pimecrolimus | 28 | $6,747 |
| Clobetasol Propionate | 71 | $3,655 |
| Metronidazole | 69 | $3,339 |
| Fluocinonide | 76 | $2,866 |
| Calcipotriene | 19 | $2,613 |
| Cimetidine | 14 | $2,132 |
| Ketoconazole | 133 | $2,050 |
| Triamcinolone Acetonide | 160 | $1,822 |
| ValacyclovirValacyclovir Hcl | 23 | $1,441 |
| Econazole Nitrate | 50 | $1,438 |
| Minocycline Hcl | 49 | $1,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $159 | $58,78812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Fort Myers
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.